Engineered Heart Repair

There is a pressing need for the development of advanced heart failure therapeutics. Current state‐of‐the‐art is protection from neurohumoral overstimulation, which fails to address the underlying cause of heart failure, namely loss of cardiomyocytes. Implantation of stem cell‐derived cardiomyocytes via tissue‐engineered myocardium is being advanced to realize the remuscularization of the failing heart. Here, we discuss pharmacological challenges pertaining to the clinical translation of tissue‐engineered heart repair with a focus on engineered heart muscle (EHM).